{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:53:42Z","timestamp":1791410022915,"version":"4.3.3"},"reference-count":78,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To compare kidney outcomes after GLP\u20101 receptor agonists (RA) or tirzepatide (GLP\u20101\/GIP RAs) versus finerenone initiation in adults with Type 2 diabetes (T2D) and moderate chronic kidney disease (CKD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In a retrospective TriNetX global network study (July 2021\u2013November 2025), adults with T2D and CKD stages 3\u20134 initiating GLP\u20101\/GIP RAs or finerenone were 1:1 propensity\u2010score matched and followed \u2264\u20092.5\u2009years. The primary endpoint was a composite of ESKD, Stage 5 CKD, or dialysis initiation. Secondary analyses compared annual total (0\u20132.5\u2009years) and chronic (0.5\u20132.5\u2009years) estimated glomerular filtration rate (eGFR) slopes. Sensitivity analyses included positive\/negative controls, extended follow\u2010up, and stratification by age, sex, baseline kidney function, glycated haemoglobin A1c, BMI, specific GLP\u20101\/GIP RA, and baseline medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 4554 individuals (43.3% women, mean age 70.7\u2009years, mean eGFR 39.4\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      ), the primary endpoint occurred in 110 (4.8%) GLP\u20101\/GIP RAs and 136 (6.0%) finerenone initiators (hazard ratio: 0.71 [95% CI: 0.55\u20130.91]; 2.5\u2010year absolute risk difference: \u22121.14% [\u22122.45 to 0.17]). Between\u2010group differences in total and chronic eGFR slope with GLP\u20101\/GIP RA versus finerenone were 1.04\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      \/year [95% CI: 0.32 to 1.75] and \u22120.08\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      \/year [95% CI, \u22121.27 to 1.12], respectively. Sensitivity analyses were consistent. Baseline albuminuria data were missing for most participants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a real\u2010world cohort, GLP\u20101\/GIP RAs versus finerenone initiation was associated with a lower relative hazard of adverse kidney outcomes, without evidence of a difference in absolute risk. This was accompanied by total, but not chronic, eGFR slope mitigation. Residual confounding from under\u2010sampled albuminuria is possible, and findings should be interpreted within this specific matched population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71402","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:45:03Z","timestamp":1791409503000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kidney Outcomes With\n                    <scp>GLP<\/scp>\n                    \u20101 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real\u2010World Cohort Study"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2689-6488","authenticated-orcid":false,"given":"Dvora R.","family":"Sehtman\u2010Shachar","sequence":"first","affiliation":[{"name":"Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"},{"name":"Diabetes Unit, Department of Endocrinology and Metabolism Hadassah Medical Center  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa","family":"Fishkin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"},{"name":"Diabetes Unit, Department of Endocrinology and Metabolism Hadassah Medical Center  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Leibowitz","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"},{"name":"Diabetes Unit, Department of Endocrinology and Metabolism Hadassah Medical Center  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofri","family":"Mosenzon","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"},{"name":"Regeneron Pharmaceuticals Inc  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5071-3143","authenticated-orcid":false,"given":"Meir","family":"Schechter","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"},{"name":"Diabetes Unit, Department of Endocrinology and Metabolism Hadassah Medical Center  Jerusalem Israel"},{"name":"Dina Recanati School of Medicine Reichman University  Herzliya Israel"},{"name":"The Gertner Institute for Epidemiology and Health Policy Research Sheba Medical Center  Ramat Gan Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genya","family":"Aharon\u2010Hananel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Hebrew University of Jerusalem  Jerusalem Israel"},{"name":"Diabetes Unit, Department of Endocrinology and Metabolism Hadassah Medical Center  Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14\u20101296"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.10.026"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(14)70156\u20101"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0003122021"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.11111016"},{"issue":"9131","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive Blood\u2010Glucose Control With Sulphonylureas or Insulin Compared With Conventional Treatment and Risk of Complications in Patients With Type 2 Diabetes (UKPDS 33)","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","journal-title":"Lancet"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802987"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.10.049"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2011.415"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2011.537"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011489"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06\u20101998"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199311113292004"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011303"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011161"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.58"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515920"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc26\u2010S011"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)31149\u20103"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505928"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.055459"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(18)30104\u20109"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1616011"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)31150\u2010X"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(26)00032\u2010X"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025845"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfac157"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.10081"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110956"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2604625"},{"issue":"6","key":"e_1_2_10_40_1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A More Accurate Method to Estimate Glomerular Filtration Rate From Serum Creatinine: A New Prediction Equation Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey A. S.","year":"1999","journal-title":"Annals of Internal Medicine"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102953"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc26\u2010S009"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70718"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.06.016"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.01.013"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167\u20109473(01)00107\u20104"},{"key":"e_1_2_10_48_1","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"Ggplot2: Elegant Graphics for Data Analysis","author":"Wickham H.","year":"2016"},{"key":"e_1_2_10_49_1","unstructured":"A.Dayimu \u201cForestploter: Create a Flexible Forest Plot \u201d2025."},{"key":"e_1_2_10_50_1","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Foundation for Statistical Computing RCT","year":"2024"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23\u20100231"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(21)00203\u20105"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.70066"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933\u2010022\u201001676\u20105"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098\u2010023\u201001251\u20102"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22\u20102904"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410659"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.071689"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003133\u20100"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00280.2019"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.201148"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00967"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2500106"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)02105\u20101"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020\u2010024\u201003945\u20107"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1125693"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(23)00159\u20106"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab045"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22\u20101699"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.17002"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15752"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20\u20102715"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21\u20100723"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.26230"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15710"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.4103\/2229\u20103485.83221"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.319.7211.670"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5705"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2022.08.012"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71402","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:45:08Z","timestamp":1791409508000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":78,"alternative-id":["10.1111\/dom.71402"],"URL":"https:\/\/doi.org\/10.1111\/dom.71402","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"2026-03-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"dom.71402"}}